| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Tubulin polymerization-IN-47 targets tubulin, the protein that polymerizes to form microtubules. By inhibiting tubulin polymerization, the compound disrupts the microtubule network essential for cell division, leading to mitotic arrest and apoptosis. The compound's potent activity against neuroblastoma cells suggests it may have broad anti-tumor activity.
|
|---|---|
| ln Vitro |
In cell-free biochemical assays, Tubulin polymerization-IN-47 inhibits tubulin polymerization. The compound prevents the polymerization of purified tubulin into microtubules. This activity is typically measured using turbidimetric assays that monitor the increase in absorbance as tubulin polymerizes into microtubules. The compound's potent anti-tubulin activity translates to its anti-proliferative effects in cells.
|
| ln Vivo |
In cell-based assays, Tubulin polymerization-IN-47 suppresses the proliferation of neuroblastoma cancer cells with IC50 values of 7 nM for Chp-134 cells and 12 nM for Kelly cells. The compound exhibits potent anti-proliferative activity against various cancer cell lines. It is being investigated for the treatment of hepatocellular carcinoma, colon cancer, lung cancer, and breast cancer. The mechanism of action involves mitotic arrest and induction of apoptosis.
|
| Enzyme Assay |
The cell-free tubulin polymerization assay involves incubation of purified tubulin with the compound at various concentrations in assembly buffer containing GTP. The reaction is incubated at 37°C, and microtubule polymerization is monitored by measuring absorbance at 340 nm. The inhibition of tubulin polymerization is determined from dose-response curves. The compound's solubility in DMSO is 125 mg/mL (332.96 mM).
|
| Cell Assay |
Cell-based assays for anti-proliferative activity involve culturing cancer cell lines (Chp-134, Kelly, and others) and treating them with Tubulin polymerization-IN-47 at concentrations ranging from 0.1 to 100 nM. Cells are incubated for 48-72 hours, and cell viability is assessed using MTT, CCK-8, or ATP-based luminescence assays. IC50 values are determined from dose-response curves. Cell cycle analysis by flow cytometry and apoptosis assays can be performed to characterize the mechanism of action.
|
| Animal Protocol |
In animal models, Tubulin polymerization-IN-47 has been evaluated for its anti-tumor activity. Typical studies involve administration of the compound to tumor-bearing mice via intraperitoneal or intravenous routes at doses determined from toxicity studies. Tumor volumes are measured, and tissues are collected for analysis of tubulin polymerization inhibition, mitotic arrest, and biomarkers of apoptosis. Efficacy is being evaluated in models of hepatocellular carcinoma, colon cancer, lung cancer, and breast cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tubulin polymerization-IN-47 have not been extensively reported. As a small molecule with molecular weight of 375.42 g/mol, the compound would be expected to have reasonable oral bioavailability and tissue penetration. The compound has good solubility in DMSO (125 mg/mL). Further pharmacokinetic studies would be required to determine plasma half-life, clearance, and metabolic pathways.
|
| Toxicity/Toxicokinetics |
Toxicity data for Tubulin polymerization-IN-47 are not well documented. As a tubulin polymerization inhibitor and mitosis inhibitor, the compound would be expected to have toxicity toward rapidly dividing cells, which could translate to bone marrow suppression, gastrointestinal toxicity, and other effects associated with anti-mitotic agents. Standard toxicity studies in rodents would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
Tubulin polymerization-IN-47 is a research compound being investigated for the treatment of various cancers including hepatocellular carcinoma, colon cancer, lung cancer, and breast cancer. The compound is a potent tubulin polymerization inhibitor and mitosis inhibitor with IC50 values of 7 nM for Chp-134 cells and 12 nM for Kelly cells. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only.
|
| Molecular Formula |
C22H21N3O3
|
|---|---|
| Molecular Weight |
375.420445203781
|
| Exact Mass |
375.158
|
| CAS # |
2834087-62-4
|
| PubChem CID |
165177911
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
485
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)C2=CN3C=CN=C(C3=N2)C4=CC(=C(C(=C4)OC)OC)OC
|
| InChi Key |
SFOULTOXUOSZBX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21N3O3/c1-14-5-7-15(8-6-14)17-13-25-10-9-23-20(22(25)24-17)16-11-18(26-2)21(28-4)19(12-16)27-3/h5-13H,1-4H3
|
| Chemical Name |
2-(4-methylphenyl)-8-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyrazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~332.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6637 mL | 13.3184 mL | 26.6368 mL | |
| 5 mM | 0.5327 mL | 2.6637 mL | 5.3274 mL | |
| 10 mM | 0.2664 mL | 1.3318 mL | 2.6637 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
